Orlistat

Orlistat has been studied in 87 papers since 2009: 10 trials and 20 observational studies in people, 3 in animals, 54 reviews; 37 in the past year. It is an approved medicine. The newest paper, Nov 19, 2026: “Weight-gain-related reporting for anti-obesity medications compared to tirzepatide in United States Food and Drug Administration Adverse Event Reporting System (FAERS)”.

InterventionApproved 1998

87 papers study it5 more mention it14 findingsUpdated

PubChemChEBIMeSH

9 new papers in 30 daysSee all 89 papers on orlistat

At a glance

The findings reach people, from one lab or study. 7 independent labs in 5 countries; 31 trials, 1 about aging, 11 with no results posted.

“Estimates were 2.30 (1.57–3.39) for orlistat, 1.63 (1.31–2.04) for phentermine-topiramate, and 1.58 (1.30–1.93) for naltrexone–bupropion.”
Weight-gain-related reporting for anti-obesity medications compared to tirzepatide in United States Food and Drug Administration Adverse Event Reporting System (FAERS)Frontiers in pharmacology2026doi:10.3389/fphar.2026.1979194

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 7 independent labs in 5 countries
  • 31 trials, 1 about aging, 11 with no results posted
  • Funders: Academy of Medical Sciences and 2 more
  • 4 of 31 trials sponsored by its developers
  • Human trial10
  • Humans20
  • Animals2

What did studies of orlistat find?

11

Studies of orlistat measured 11 outcomes, among them body weight, Fat-soluble vitamin absorption and triglyceride.

Body weight

downin humans1downin reviews1

2 studies
  1. Orlistat is linked with lower body weight in humans (-1.2 kg (p=0.002)).

    “At 12-16 weeks after starting orlistat and liraglutide, weight losses of -1.2kg (p=0.002) and -4.1kg (p<0.001) were observed, respectively”

    Humans12-16 weeks

    Effectiveness, persistence of use, and safety of orlistat and liraglutide in a group of patients with obesity

    Expert opinion on pharmacotherapy

  2. Orlistat decreases body weight.

    “which is an inhibitor of pancreatic and hepatic lipases that induces weight loss”

    Review

    Lipid Hydrolase Enzymes: Pragmatic Prolongevity Targets for Improved Human Healthspan?

    Rejuvenation research

Fat-soluble vitamin absorption

downin reviews1

1 study
  1. Orlistat decreases fat-soluble vitamin absorption (due to inhibition of intestinal fat absorption).

    “Orlistat has been consistently associated with reduced absorption of fat-soluble vitamins due to inhibition of intestinal fat absorption”

    Reviewdue to inhibition of intestinal fat absorption

    Nutritional deficiencies associated with anti-obesity pharmacotherapy

    International Journal of Community Medicine and Public Health

Triglyceride

no changein humans1

1 study
  1. Orlistat showed no clear effect on triglyceride in humans (primary analysis in adults with dyslipidemia) (SMD -0.1668, 95% CI -0.7979 to 0.4642).

    “TG: SMD [95% CI] -0.1668 [-0.7979; 0.4642], I 2 = 97.7% p value (heterogeneity) < 0.0001”

    Reviewprimary analysis in adults with dyslipidemian = 1,369

    Long-Term Effects of Orlistat on Lipid Metabolism and Anthropometric Indices: A Meta-Analysis of Clinical Trials

    Journal of obesity

More on Triglyceride

Waist circumference

no changein humans1

1 study
  1. Orlistat showed no clear effect on waist circumference in humans (primary analysis in adults with dyslipidemia) (SMD -0.1562, 95% CI -0.3138 to 0.0015).

    “Changes in waist circumference (WC) and triglycerides (TGs) did not reach statistical significance in the primary analysis”

    Reviewprimary analysis in adults with dyslipidemian = 1,369

    Long-Term Effects of Orlistat on Lipid Metabolism and Anthropometric Indices: A Meta-Analysis of Clinical Trials

    Journal of obesity

More on Waist circumference

HDL-C

downin humans1

1 study
  1. Orlistat decreases HDL-C in adults with dyslipidemia (SMD -0.31, 95% CI -0.48 to -0.13).

    “it was associated with a decrease in high-density lipoprotein cholesterol (SMD (95% CI): -0.31 [-0.48, -0.13]”

    Reviewin adults with dyslipidemian = 1,369

    Long-Term Effects of Orlistat on Lipid Metabolism and Anthropometric Indices: A Meta-Analysis of Clinical Trials

    Journal of obesity

More on HDL-C

Body mass index

downin humans1

1 study
  1. Orlistat decreases body mass index in adults with dyslipidemia (SMD -0.30, 95% CI -0.58 to -0.03).

    “Orlistat reduced body mass index (BMI) (SMD [95% CI]: -0.30 [-0.58, -0.03], p value (heterogeneity) = 0.026)”

    Reviewin adults with dyslipidemian = 1,369

    Long-Term Effects of Orlistat on Lipid Metabolism and Anthropometric Indices: A Meta-Analysis of Clinical Trials

    Journal of obesity

More on Body mass index

Blood pressure

no changein humans1

1 study
  1. Orlistat showed no clear effect on blood pressure in humans (metabolic dysfunction-associated steatotic liver disease).

    “Orlistat did not significantly affect BP.”

    Reviewmetabolic dysfunction-associated steatotic liver disease

    Efficacy of Orlistat on Cardiometabolic Indices in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A GRADE-Assessed Systematic Review and Meta-Analysis of RCTs

    Current therapeutic research, clinical and experimental

Body mass index

downin humans1

1 study
  1. Orlistat decreases body mass index in humans (metabolic dysfunction-associated steatotic liver disease) (WMD -0.99 kg/m2, 95% CI -1.18 to -0.81).

    “BMI decreased significantly overall (WMD: -0.99 kg/m2, 95% CI: -1.18 to -0.81, P < 0.001), with stronger effects in long-term interventions.”

    Reviewmetabolic dysfunction-associated steatotic liver disease

    Efficacy of Orlistat on Cardiometabolic Indices in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A GRADE-Assessed Systematic Review and Meta-Analysis of RCTs

    Current therapeutic research, clinical and experimental

Alanine aminotransferase

downin humans1

1 study
  1. Orlistat decreases alanine aminotransferase in humans (metabolic dysfunction-associated steatotic liver disease) (WMD -8.70 U/L, 95% CI -16.51 to -0.90).

    “ALT (WMD: -8.70 U/L, 95% CI: -16.51 to -0.90, P = 0.036)”

    Reviewmetabolic dysfunction-associated steatotic liver disease

    Efficacy of Orlistat on Cardiometabolic Indices in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A GRADE-Assessed Systematic Review and Meta-Analysis of RCTs

    Current therapeutic research, clinical and experimental

More on Alanine aminotransferase

Gastrointestinal discomfort

upin humans1

1 study
  1. Orlistat increases gastrointestinal discomfort in humans.

    “side effects such as gastrointestinal discomfort with orlistat and GLP-1 receptor agonists”

    Review

    Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review

    Cureus

All 11

What is orlistat linked with?

2

Studies link orlistat with 2 measures: Weight-gain-related reporting and steatorrhea.

Weight-gain-related reporting

upin humans1

1 study
  1. Orlistat is associated with weight-gain-related reporting in humans (Compared with tirzepatide; five-term reporting definition) (Adjusted reporting odds ratio 2.30 (95% CI 1.57–3.39)).

    “Estimates were 2.30 (1.57–3.39) for orlistat, 1.63 (1.31–2.04) for phentermine-topiramate, and 1.58 (1.30–1.93) for naltrexone–bupropion.”

    HumansCompared with tirzepatide; five-term reporting definition2023–2025

    Weight-gain-related reporting for anti-obesity medications compared to tirzepatide in United States Food and Drug Administration Adverse Event Reporting System (FAERS)

    Frontiers in pharmacology

Steatorrhea

upin humans1

1 study
  1. Orlistat is associated with steatorrhea in humans.

    “Orlistat commonly linked to steatorrhea and flatulence”

    Review

    Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review

    Medicina (Kaunas, Lithuania)

Has orlistat been tested in people?

1 of 31 about aging

Yes: 10 trials and 20 observational studies in people have been published, and 30 trials are registered.

Approved

Repurposing

All 18

Every condition in trials

  • Hyperlipoproteinemia Type I

    Phase 2Results posted1 trial

Stopped

  • NCT00115063TerminatedObesity

    ethical issues of continuing control group without treatment

  • NCT04531176TerminatedObesity

    After an unplanned yet IRB approved interim analysis, it was found that there was not a significant difference between the 3 arms of the study. The study was closed due to futility. All Patients are off study and this study will not resume.

  • NCT01351753TerminatedDyslipidemias

    Lack of funding

  • NCT01675154TerminatedHypertriglyceridemia

    Due to unavailability of the drug.

Trial sponsors

Latest

Dec 2025: 4Jan 2026: 5Feb 2026: 4Mar 2026: 3Apr 2026: 0May 2026: 1Jun 2026: 3Jul 2026: 1Aug 2026: 2Sep 2026: 6Oct 2026: 5Nov 2026: 337 papers in 12 months

See all 89 papers on orlistat